The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for game-changing treatments and impressive returns is undeniable, the linked risks are also signific… Read More